Abstract: Described herein are virus-like particles (VLPs) that were generated to present the viral glycoprotein antigens on their surface, coupled to magnetic fluorescent microspheres to create VLP-conjugated microspheres (VCMs) and methods of making them. These VCMs were stable when lyophilized and stored at 37° C. and able to detect antibodies in non-human primate (NHP) and human clinical sera at dilutions of 1×105 and 1×104, respectively. Methods are also disclosed for detecting an immune response using VCMs.

Abstract: Disclosed herein are nucleotide sequences which encode a plurality of structural proteins, except the capsid, of an equine encephalitis virus, wherein the nucleotide sequence is codon-optimized for mammalian expression. The nucleotide sequences are codon-optimized for expression in humans. As disclosed herein, the nucleotide sequences confer protection against Venezuelan equine encephalitis virus (VEEV), western equine encephalitis virus (WEEV), and/or eastern equine encephalitis virus (EEEV).

Abstract: Disclosed herein are nucleotide sequences which encode a plurality of structural proteins, except the capsid, of an equine encephalitis virus, wherein the nucleotide sequence is codon-optimized for mammalian expression. The nucleotide sequences are codon-optimized for expression in humans. As disclosed herein, the nucleotide sequences confer protection against Venezuelan equine encephalitis virus (VEEV), western equine encephalitis virus (WEEV), and/or eastern equine encephalitis virus (EEEV).

Abstract: The invention relates to DNA vaccines that target multiple arenavirus agents singly or simultaneously.

Abstract: Three vectors are described which allow the conversion of Fab fragments into or single chain Fv fragments into full-length antibody molecules. Methods for using the vectors and the resulting antibodies are also described.

Abstract: In this application is described a protective DNA vaccines against infection with HFRS- and HPS-associated hantaviruses. The vaccines were constructed by subcloning cDNA representing the medium (M) (encoding the G1 and G2 glycoproteins) into the DNA expression vector pWRG7077. Animals vaccinated with the M construct developed a neutralizing antibody response. Passive transfer experiments show that serum from vaccinated animals, when injected on days 4 or 5 after challenge, protected animals from lethal disease.

Abstract: Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding an antigen from Bacillus anthracis. Vectors and compositions containing these molecules are also described. Methods for eliciting an immune response using these molecules and compositions are also described.

Abstract: In this application is described a protective DNA vaccines against infection with HFRS- and HPS-associated hantaviruses. The vaccines were constructed by subcloning cDNA representing the medium (M) (encoding the G1 and G2 glycoproteins) into the DNA expression vector pWRG7077. Animals vaccinated with the M construct developed a neutralizing antibody response. Passive transfer experiments show that serum from vaccinated animals, when injected on days 4 or 5 after challenge, protected animals from lethal disease.

Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.

Abstract: In this application is described a poxvirus naked DNA vaccine which protects animals against poxvirus challenge comprising IMV and EEV nucleic acids from poxvirus. Methods of use of the vaccine and its advantages are described.

Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.

Abstract: Three vectors are described which allow the conversion of Fab fragments into or single chain Fv fragments into full-length antibody molecules. Methods for using the vectors and the resulting antibodies are also described.

Abstract: In this application is described a poxvirus naked DNA vaccine which protects animals against poxvirus challenge comprising IMV and EEV nucleic acids from poxvirus. Methods of use of the vaccine and its advantages are described.

Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.

Abstract: Seoul virus (SEOV) is one of four known hantaviruses causing hemorrhagic fever with renal syndrome (HFRS). Candidate naked DNA vaccines for HFRS were constructed by subcloning cDNA representing the medium (M) (encoding the G1 and G2 glycoproteins) or small (S) (encoding the nucleocapsid protein) genome segment of SEOV into the DNA expression vector pWRG7077. We vaccinated BALB/c mice with three doses of the M or S DNA vaccine at 4-week intervals by either gene gun inoculation of the epidermis, or needle inoculation into the gastrocnemius muscle. Both routes of vaccination resulted in antibody responses as measured by ELISA; however, gene gun inoculation elicited a higher frequency of seroconversion, and higher levels of antibodies in individual mice. We vaccinated Syrian hamsters with the M or S construct using the gene gun and found hantavirus-specific antibodies in 5/5 and 4/5 hamsters, respectively.

Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.

Abstract: Particle mediated immunization of tick-borne flavivirus genes confers homologous and heterologous protection against tick borne encephalitis.

Abstract: An approach to genetic vaccine methodology is described. A genetic construction encoding antigenic determinants of a filovirus is transfected into cells of the vaccinated individuals using a particle acceleration protocol so as to express the viral antigens in healthy cells to produce an immune response to those antigens.

Abstract: Vaccine formulations for inducing protective immune response to Hantaviruses in humans are disclosed. These formulations include an attenuated vaccinia virus vector containing cDNA's encoding Hantavirus nucleocapsid N protein, G1 and G2 glycoproteins. Methods for the use of these formulations also are disclosed.

Abstract: Nucleotide sequences coding for Hantaan virus nucleocapsid protein and glproteins G1 and G2 can be used to produce these proteins for vaccine and diagnostic applications.